US Patent 9,623,022: Dasabuvir Sodium HCV Treatment Claims and Patent Landscape

US Patent 9,623,022 is a method-of-treatment patent covering administration of dasabuvir, including dasabuvir sodium, for hepatitis C virus infection. Its strongest commercial scope is directed to genotype 1 HCV treatment, particularly combination therapy with other direct-acting antivirals, ribavirin, and pegylated interferon-alpha. The patent does not broadly claim the dasabuvir molecule, a tablet formulation, or a manufacturing process. Its enforceable value therefore depends on whether a competing product practices the claimed treatment regimen.

What drug does US Patent 9,623,022 protect?

The compound represented by the omitted chemical formula in the claims is dasabuvir, also known as ABT-333. Dasabuvir is a non-nucleoside HCV NS5B polymerase inhibitor developed by AbbVie. The sodium salt is the active pharmaceutical ingredient used in AbbVie's HCV regimen.

Patent element	Scope
Patent	US 9,623,022 B2
Patent type	Method of treatment
Active ingredient	Dasabuvir, including dasabuvir sodium
Primary target	HCV NS5B polymerase
Principal genotype	HCV genotype 1
Combination agents	Polymerase inhibitors, protease inhibitors, other HCV agents, ribavirin, pegylated interferon-alpha
Administration	Simultaneous, separate, or sequential
Commercial product association	Exviera and Viekira Pak
Patent holder	AbbVie-related entities
Issue date	April 18, 2017
Earliest relevant priority period	Approximately 2010
Base patent-term endpoint	Approximately 2031, before any applicable patent-term adjustment

The claims are treatment claims rather than composition-of-matter claims. A product can contain dasabuvir without infringing the patent unless it is made, sold, or used for a claimed HCV treatment method.

What are the independent and dependent claims in US 9,623,022?

Claim 1 is the principal independent claim. It covers treating an HCV-infected patient by administering the claimed compound or a pharmaceutically acceptable salt.

Claims 2 through 16 narrow that method through the following limitations:

The compound is administered as a sodium salt.
The patient has HCV genotype 1.
Another anti-HCV agent is administered.
The second agent is an HCV polymerase inhibitor, protease inhibitor, antiviral, immunomodulator, or agent directed to another HCV-life-cycle target.
The second agent is ribavirin.
The second agent is pegylated interferon-alpha.
Both ribavirin and pegylated interferon-alpha are used.
The dasabuvir sodium, ribavirin, and pegylated interferon-alpha regimen is administered.
The agents are administered simultaneously.
The agents are administered separately.
The agents are administered sequentially.

The claim structure creates a descending hierarchy. Claim 1 is the broadest treatment claim. Claim 2 narrows the active ingredient to the sodium salt. Claims 3 through 13 narrow the patient population and treatment combination. Claims 14 through 16 preserve coverage across different dosing schedules.

How strong is the patent estate for dasabuvir?

The estate is strongest where a competing product uses dasabuvir sodium to treat genotype 1 HCV, particularly as part of a combination regimen. It is weaker against products that:

do not contain dasabuvir;
contain dasabuvir but are not indicated for HCV treatment;
treat non-genotype 1 HCV;
use a different salt or formulation;
rely on a different treatment method;
are used outside the United States;
are not marketed with instructions that induce the claimed combination or sequence.

The patent does not appear, from the supplied claims, to protect:

the underlying dasabuvir chemical composition;
a specific tablet, capsule, or solid dosage form;
particle size, polymorph, excipient, or coating;
a process for synthesizing dasabuvir;
a method for manufacturing dasabuvir sodium;
a fixed-dose combination composition;
a specific treatment duration;
a viral-load endpoint or sustained virologic response endpoint.

Those subjects would normally be covered by separate compound, formulation, combination-composition, or manufacturing patents.

What formulation patents protect dasabuvir products?

US 9,623,022 is not a formulation patent. Its claims do not require a particular dosage form or excipient system. A generic or follow-on developer could therefore face separate patent issues involving:

dasabuvir sodium solid-state form;
tablet composition;
immediate-release delivery;
co-formulation with ombitasvir, paritaprevir, and ritonavir;
packaging and stability;
manufacturing controls;
salt formation and crystallization;
fixed-dose combination ratios.

The principal commercial product was not a single-agent dasabuvir therapy. Dasabuvir was used in AbbVie's multi-drug HCV regimens. The relevant patent analysis therefore requires review of the broader AbbVie estate covering ombitasvir, paritaprevir, ritonavir combinations, and the Viekira Pak product configuration.

What was the FDA status of dasabuvir?

The FDA approved dasabuvir as part of AbbVie's genotype 1 HCV treatment platform. Viekira Pak contained ombitasvir, paritaprevir, ritonavir, and dasabuvir. Technivie contained ombitasvir, paritaprevir, and ritonavir without dasabuvir.

The regulatory architecture matters because US 9,623,022 is directed to treatment conduct, while Orange Book-listed patents can include distinct patents covering:

active ingredients;
fixed-dose combinations;
methods of use;
dosage regimens;
formulations;
product-specific combinations.

The original clinical role of dasabuvir was the treatment of genotype 1 HCV, with regimen selection depending on subtype, cirrhosis status, prior treatment, and ribavirin use. The FDA later approved newer pangenotypic regimens that reduced the commercial importance of dasabuvir-based therapy. FDA treatment guidance now places greater emphasis on pangenotypic direct-acting antiviral combinations rather than older interferon-based regimens.[1]

What is the Orange Book status of US 9,623,022?

US 9,623,022 should be evaluated against the FDA Orange Book entries for the relevant approved drug product rather than analyzed in isolation. Orange Book status can differ between a patent's issuance date, listing date, use code, and enforceable scope.

A method patent listed for dasabuvir or a dasabuvir-containing product can create a Paragraph IV exposure for an ANDA applicant if the applicant's proposed labeling includes the patented use. The risk is highest where the proposed label:

identifies genotype 1 HCV;
identifies dasabuvir or dasabuvir sodium;
directs use with another HCV agent;
recommends ribavirin or interferon;
instructs simultaneous or sequential administration.

A label that omits the patented indication may reduce inducement risk, but it does not eliminate potential infringement if the product is marketed with other materials that encourage the claimed use. The Orange Book patent listing and use code must therefore be compared with the proposed ANDA label and any skinny-label carve-out.

When does US 9,623,022 lose exclusivity?

The patent has a base term running approximately 20 years from its earliest nonprovisional filing date. Based on the patent's priority period, the base term is expected to reach into 2031, subject to any terminal disclaimer, patent-term adjustment, or other USPTO term calculation.

Exclusivity category	Expected position
Patent term	Approximately through 2031
FDA new-drug exclusivity	Expired
Orphan exclusivity	Not the principal protection
Regulatory exclusivity for the original HCV regimen	Expired
Patent-term extension	Must be checked against the specific NDA and Orange Book record
Practical current barrier	Remaining patents, labeling, formulation, and combination-product rights

FDA regulatory exclusivity for the original Viekira Pak approval is no longer the primary barrier. Any remaining commercial protection depends mainly on patent term and the scope of related patents. A patent's expiration does not automatically clear every patent associated with the drug.

What Paragraph IV challenges could affect the patent?

An ANDA applicant seeking approval for a dasabuvir-containing product could use a Paragraph IV certification against a listed patent. The applicant would assert that the patent is invalid, unenforceable, or not infringed. The patent owner could then file an action under the Hatch-Waxman framework, triggering the statutory 30-month stay if the statutory requirements are satisfied.[2]

For US 9,623,022, the principal Paragraph IV arguments would likely focus on:

Non-infringement

A challenger could argue that its label does not direct treatment of genotype 1 HCV, does not require the claimed co-administered agent, or does not instruct simultaneous, separate, or sequential administration within the meaning of the claims.

Invalidity

Potential invalidity theories could include:

anticipation by an earlier publication or clinical protocol;
obviousness based on prior HCV polymerase-inhibitor combinations;
written-description deficiencies;
enablement issues across the full scope of the compound and treatment claims;
indefiniteness in the chemical definition or treatment limitations.

The practical strength of those defenses depends on the complete patent specification, prosecution history, cited prior art, and any continuation or divisional history. The claim language supplied here alone does not establish whether any particular validity challenge would succeed.

Section viii carve-out

If the listed patent covers only a method of use and the applicant seeks approval for a noncovered use, a section viii statement may be available. A carve-out becomes difficult where the remaining label necessarily instructs use within the patented genotype 1 combination regimen.

Which companies challenged the dasabuvir patent estate?

The commercial challenge landscape was shaped by the rapid shift from older genotype-specific regimens to pangenotypic HCV products. The main competitive products included:

Company	Product or platform	Competitive position
Gilead Sciences	Sovaldi, Harvoni, Epclusa, Vosevi	Competing direct-acting antiviral franchise
Merck	Zepatier	Genotype 1 and genotype 4 competition
Bristol Myers Squibb	Daklinza	Earlier NS5A-based competition
AbbVie	Viekira Pak, Technivie, Exviera	Dasabuvir-containing franchise
Generic manufacturers	Potential post-expiry entrants	Dependent on Orange Book, formulation, and combination patents

Public competition against the dasabuvir estate was not limited to direct Paragraph IV litigation. Pangenotypic products reduced the addressable market without practicing the dasabuvir claims. That distinction matters: market displacement is not the same as patent invalidation.

What patent litigation affects US 9,623,022?

The principal litigation risk is an ANDA action involving a proposed dasabuvir or dasabuvir-combination product. The relevant inquiry is whether a public case docket identifies:

an ANDA number;
a Paragraph IV notice;
an infringement complaint;
a preliminary injunction;
a settlement;
a consent judgment;
a license or authorized-generic arrangement.

The supplied claim set does not identify a litigation event, settlement, or license. A patent-number-only review cannot attribute a specific Paragraph IV action or settlement to US 9,623,022 without the associated court docket and Orange Book listing record.

How does US 9,623,022 compare with compound and formulation patents?

Patent category	Typical protected subject	Relevance to US 9,623,022
Compound patent	Dasabuvir chemical structure	Broader product protection than the supplied claims
Salt patent	Dasabuvir sodium or another salt	Potentially overlaps claim 2
Formulation patent	Tablet, excipients, release profile	Separate from the method claims
Combination patent	Dasabuvir with ombitasvir, paritaprevir, ritonavir	Potentially material to Viekira Pak
Method-of-use patent	Treatment of HCV, genotype, regimen	Direct category of US 9,623,022
Manufacturing patent	Synthesis, purification, crystallization	Separate technical barrier
Regulatory patent listing	NDA-linked Orange Book protection	Determines ANDA certification exposure

US 9,623,022 is commercially meaningful because treatment patents can block approval or marketing instructions even after a compound patent expires. Its weakness is that the claims are limited by the treatment context and do not independently control the active ingredient as a product.

What generic launch scenarios exist?

Launch after patent expiration

A generic could launch after the relevant US 9,623,022 term ends if no unexpired compound, formulation, combination, or manufacturing patent blocks the product.

Skinny-label launch

A generic could attempt to remove the patented genotype 1 or combination indication from its label. The feasibility depends on the remaining approved uses and whether the product's labeling, promotional materials, or distribution practices would still induce infringement.

Paragraph IV launch

A challenger could launch before expiry after providing a Paragraph IV notice and prevailing in litigation, obtaining a favorable settlement, or accepting the risk of an infringement action.

Authorized or licensed launch

AbbVie could license the product, enter a settlement, or authorize a generic. Such an arrangement would alter the practical launch date without changing the patent's formal expiration.

What is the geographic coverage of US 9,623,022?

The patent has territorial effect only in the United States. Corresponding international applications may create separate rights in Europe, Canada, Japan, and other jurisdictions, but foreign family members require independent review of:

grant status;
claim scope;
opposition proceedings;
supplementary protection certificates;
local patent-term adjustments;
national litigation;
local regulatory approvals.

A US judgment or Orange Book listing has no direct legal effect on foreign markets.

Key Takeaways

US 9,623,022 is a method-of-treatment patent associated with dasabuvir, including dasabuvir sodium.
Its central commercial scope covers treatment of HCV, with narrower claims focused on genotype 1 and combination therapy.
Claims 14 through 16 cover simultaneous, separate, and sequential administration.
The patent does not, based on the supplied claims, protect a tablet formulation, manufacturing process, or the dasabuvir molecule as such.
FDA regulatory exclusivity for the original AbbVie HCV products has expired, but related patents may remain relevant.
A generic challenge would likely focus on label scope, induced infringement, obviousness, written description, and the interaction with other Orange Book-listed patents.
The base patent term is expected to extend approximately to 2031, subject to the official USPTO term calculation.
The strongest residual risk is for a competing dasabuvir-containing product labeled for genotype 1 HCV combination treatment.

FAQs

Does US 9,623,022 cover dasabuvir sodium itself?

No. Claim 2 addresses administration of dasabuvir sodium in a treatment method. It does not, by itself, claim the sodium salt as a standalone chemical composition.

Does the patent cover Viekira Pak?

It can cover use of a Viekira Pak-type regimen where the product is used to treat genotype 1 HCV under the claimed combination and administration conditions. Other patents may separately cover the product's composition.

Can a generic launch without using dasabuvir?

Yes. A product that does not contain dasabuvir would generally not practice the active-ingredient limitation of the claims, although it could face patents directed to other HCV agents.

Can a generic omit genotype 1 from its label?

A label carve-out may reduce direct method-of-use exposure, but the result depends on the complete approved label, promotional conduct, Orange Book use code, and other listed patents.

Does expiration of US 9,623,022 eliminate all AbbVie HCV patent risk?

No. Compound, salt, formulation, combination, manufacturing, and separate method-of-use patents can have different expiration dates and claim scope.

References

U.S. Food and Drug Administration. (n.d.). Viekira Pak prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
United States Patent and Trademark Office. (2017). U.S. Patent No. 9,623,022 B2: Methods of treating hepatitis C virus infection. USPTO.
U.S. Food and Drug Administration. (n.d.). Small business assistance: Frequently asked questions on the patent certification process. FDA.
United States Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355 and 35 U.S.C. §§ 156, 271, 282.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Prods	OLYSIO	simeprevir sodium	CAPSULE;ORAL	205123-001	Nov 22, 2013		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				METHOD OF TREATING HEPATITIS C	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1912999	⤷ Start Trial	CA 2014 00053	Denmark	⤷ Start Trial
European Patent Office	1912999	⤷ Start Trial	C300697	Netherlands	⤷ Start Trial
European Patent Office	1912999	⤷ Start Trial	PA2014036	Lithuania	⤷ Start Trial
European Patent Office	1912999	⤷ Start Trial	1490062-5	Sweden	⤷ Start Trial
European Patent Office	1912999	⤷ Start Trial	14C0076	France	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,623,022

Which drugs does patent 9,623,022 protect, and when does it expire?

Summary for Patent: 9,623,022